These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 7662199)

  • 1. Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study.
    Dorrucci M; Rezza G; Vlahov D; Pezzotti P; Sinicco A; Nicolosi A; Lazzarin A; Galai N; Gafà S; Pristerà R
    AIDS; 1995 Jun; 9(6):597-604. PubMed ID: 7662199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. The Italian Seroconversion Study.
    AIDS; 1992 Apr; 6(4):421-6. PubMed ID: 1616637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
    Dorrucci M; Pezzotti P; Phillips AN; Alliegro MB; Rezza G
    AIDS; 1997 Mar; 11(4):461-7. PubMed ID: 9084793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.
    Cozzi Lepri A; Pezzotti P; Dorrucci M; Phillips AN; Rezza G
    BMJ; 1994 Dec; 309(6968):1537-42. PubMed ID: 7819892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study.
    Prins M; Veugelers PJ
    AIDS; 1997 Apr; 11(5):621-31. PubMed ID: 9108944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users.
    Prins M; Hernández Aguado IH; Brettle RP; Robertson JR; Broers B; Carré N; Goldberg DJ; Zangerle R; Coutinho RA; van den Hoek A
    AIDS; 1997 Nov; 11(14):1747-56. PubMed ID: 9386810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
    Wannamethee SG; Sirivichayakul S; Phillips AN; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
    Int J Epidemiol; 1998 Apr; 27(2):289-95. PubMed ID: 9602412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis.
    Hendriks JC; Satten GA; van Ameijden EJ; van Druten HA; Coutinho RA; van Griensven GJ
    AIDS; 1998 Aug; 12(12):1537-44. PubMed ID: 9727576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of rapid progression to AIDS in HIV-1 seroconverters.
    Keet IP; Krijnen P; Koot M; Lange JM; Miedema F; Goudsmit J; Coutinho RA
    AIDS; 1993 Jan; 7(1):51-7. PubMed ID: 8095146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS.
    Maas JJ; Dukers N; Krol A; van Ameijden EJ; van Leeuwen R; Roos MT; de Wolf F; Coutinho RA; Keet IP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):254-9. PubMed ID: 9803967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study.
    Phillips AN; Pezzotti P; Lepri AC; Rezza G
    AIDS; 1994 Sep; 8(9):1299-305. PubMed ID: 7802984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study.
    Rezza G
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 17 Suppl 1():S13-6. PubMed ID: 9586645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired immunodeficiency syndrome (AIDS) risk in recent and long-standing human immunodeficiency virus type 1 (HIV-1)-infected patients with similar CD4 lymphocyte counts.
    Phillips AN; Sabin CA; Elford J; Bofill M; Janossy G; Lee CA
    Am J Epidemiol; 1993 Nov; 138(10):870-8. PubMed ID: 7901990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study.
    Pezzotti P; Galai N; Vlahov D; Rezza G; Lyles CM; Astemborski J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):275-82. PubMed ID: 10077177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users.
    Alcabes P; Muñoz A; Vlahov D; Friedland G
    Ann Epidemiol; 1994 Jan; 4(1):17-26. PubMed ID: 7911376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural history of HIV infection in intravenous drug users: risk of disease progression in a cohort of seroconverters.
    Rezza G; Lazzarin A; Angarano G; Sinicco A; Pristerà R; Ortona L; Barbanera M; Gafà S; Tirelli U; Salassa B
    AIDS; 1989 Feb; 3(2):87-90. PubMed ID: 2496724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of AIDS in HIV seroconverters: a comparison between intravenous drug users and homosexual males.
    Rezza G; Lazzarin A; Angarano G; Zerboni R; Sinicco A; Salassa B; Pristerà R; Barbanera M; Ortona L; Aiuti F
    Eur J Epidemiol; 1990 Mar; 6(1):99-101. PubMed ID: 2188852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
    Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users.
    Alcabes P; Selwyn PA; Davenny K; Hartel D; Buono D; Schoenbaum EE; Klein RS; Friedland GH
    AIDS; 1994 Jan; 8(1):107-15. PubMed ID: 7912083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.